TRT Monitoring: A Complete Physician Guide to Lab Tracking

TRT monitoring means regularly checking testosterone levels, blood counts, prostate markers and overall health after starting testosterone replacement therapy, so that benefits are maximized and side effects are caught early. Professional guidelines recommend a structured schedule — typically a reassessment within the first 3 to 12 months and at least yearly after that — with specific thresholds that call for action. Good monitoring is what separates medical testosterone therapy from simply raising a number.

Why TRT Monitoring Matters

Testosterone is an FDA-approved treatment for men with confirmed hypogonadism: consistent symptoms plus unequivocally low morning testosterone on repeat testing. Labeled dosing exists for each formulation, but the right regimen differs from person to person, and the body's response changes over time.

Testosterone affects red blood cell production, the prostate, fertility, blood pressure, lipids, mood and sleep. Most of these effects are manageable when they are watched. Problems usually arise when therapy is started without a baseline or continued without follow-up. If you have not started yet, read TRT Guide: What Patients Need to Know Before Starting first.

Baseline: What to Check Before Starting

A proper baseline answers two questions: is testosterone therapy appropriate, and what are we comparing future results to?

• Total testosterone, measured twice on separate mornings, fasting, ideally before 10 a.m.
• Free testosterone or SHBG when total testosterone is borderline or SHBG may be abnormal (for example, with obesity, aging, thyroid disease or liver disease)
• LH and FSH to distinguish testicular causes from pituitary or hypothalamic causes
• Prolactin and further pituitary evaluation when LH and FSH are low or inappropriately normal
• Complete blood count, especially hematocrit
• PSA, for men in the age range where prostate screening is discussed or at elevated risk
• Metabolic panel, lipids and HbA1c
• Screening for sleep apnea, which both lowers testosterone and raises the risk of high hematocrit on therapy

Fertility deserves explicit discussion before starting. Testosterone therapy suppresses sperm production. Men who want children in the near future may be better served by approaches that preserve the body's own signaling, such as those discussed in Enclomiphene vs TRT and HCG for Fertility and Testosterone Support.

The TRT Monitoring Schedule

The Endocrine Society's clinical practice guideline offers a widely used framework. In practice, I adapt it to the individual, but the core looks like this:

How to Interpret the Key Labs

Testosterone level

The goal is generally a level in the mid-normal range for healthy young men, along with improvement in the symptoms that prompted treatment. Timing matters: the result depends on when blood is drawn relative to the last dose. With injections, a draw midway between doses is a common reference point. A single high or low value without context can lead to unnecessary changes.

Hematocrit

Rising hematocrit (the percentage of blood made up of red cells) is the most common lab problem on TRT. Endocrine Society guidance recommends stopping therapy if hematocrit exceeds 54 percent, evaluating for contributing factors such as sleep apnea, smoking or high altitude, and restarting at a reduced dose once it normalizes. Starting therapy when hematocrit is already elevated generally warrants evaluation first.

PSA and the prostate

Testosterone therapy is avoided in men with untreated prostate cancer. For men who are being screened, guideline thresholds for urologic referral include a PSA increase of more than 1.4 ng/mL within 12 months of starting, a confirmed PSA above 4.0 ng/mL, or an abnormal prostate exam. Urinary symptoms should also be reviewed.

Estradiol, lipids and blood sugar

Testosterone is partly converted to estradiol, which supports bone and other functions. Routine estradiol testing is not required by guidelines, but I check it selectively, for example when breast tenderness develops. Lipids, HbA1c and blood pressure are tracked because testosterone can modestly affect each, and because cardiovascular risk management is part of comprehensive care.

What the TRAVERSE Trial Changed

For years, uncertainty about heart risk shaped testosterone prescribing. The TRAVERSE trial, published in 2023, randomized more than 5,000 men with hypogonadism and pre-existing or high cardiovascular risk to testosterone gel or placebo. Testosterone was non-inferior to placebo for major adverse cardiovascular events. However, the testosterone group had higher rates of atrial fibrillation, acute kidney injury and pulmonary embolism.

Monitoring at Laeeq M.D.

At Laeeq M.D., TRT monitoring follows a written schedule that we review together, with labs drawn locally and results discussed in a dedicated visit rather than left in a portal. We look at trends over time, not single values, and we adjust only when the full clinical picture supports it. Lab review visits are available separately, and you can see current fees on our pricing page. Patients in Virginia, Maryland, Florida, Texas, California, Pennsylvania and Tennessee can be followed virtually or in person.

Sources

• Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline — Bhasin S, et al. Journal of Clinical Endocrinology & Metabolism, 2018
• Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE) — Lincoff AM, et al. New England Journal of Medicine, 2023

Book a Consultation

Whether you are considering testosterone therapy or already on it and unsure your monitoring is complete, a careful review can make treatment safer and more effective. Dr. Laeeq offers 60-minute evaluations, virtually or in person in Reston, VA. Book a consultation to review your labs and plan.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.